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ABSTRACT  
Musculoskeletal ultrasound (MSUS) 
has become a relevant part of rheuma-
tology practice and research because 
it substantially allows us to optimise 
management of rheumatic and muscu-
loskeletal diseases. This non-invasive 
imaging modality is a valuable point-
of-care tool to accurately evaluate 
intra-articular and periarticular struc-
tures involved in a wide range of rheu-
matic diseases in adults and children. 
In addition, MSUS is an invaluable 
bedside aid for guiding accurate and 
safe musculoskeletal aspirations, injec-
tions and biopsies. This review provides 
an overview of the literature of the last 
year on the role of MSUS in arthritis. 
Introduction
Over the past two decades, muscu-
loskeletal (MS) ultrasound (US) has 
played an increasingly important role 
in optimising diagnosis, assessment, 
and monitoring of patients with rheu-
matic and musculoskeletal diseases 
(1). High-resolution grey-scale (GS) 
US and highly sensitive Doppler mode 
resulting from technological improve-
ments allow an accurate and sensitive 
evaluation of joint inflammation and 
structural damage in rheumatoid ar-
thritis (RA), spondyloarthitis (SpA), 
and osteoarthritis (OA). US is now also 
increasingly being used in the diagno-
sis and monitoring of microcrystalline 
arthropathies, connective tissue diseas-
es, vasculitis, and paediatric musculo-
skeletal diseases. Furthermore, MSUS 
is a valuable bedside tool for guiding 
accurate and safe MS diagnostic fluid 
aspiration or biopsies and peri- or intra-
lesional therapeutic injections (2). A 
great research effort, particularly by the 
Outcome Measures in Rheumatology 
(OMERACT) MSUS group, is being 
undertaken to validate MSUS in rheu-
matic diseases as well as to standardise 
US scanning technique and definitions 
of abnormalities in order to overcome 
the intrinsic operator-dependent nature 
of this imaging modality (3). The ad-
vantages of US such as non-invasive-
ness, availability, relative low cost, re-
peatability, and high patient-acceptance 
facilitate its progressive implementa-
tion in rheumatologic clinics all over 
the world. This review provides an 
evidence-based update on the role of 
MSUS in arthritis, i.e. RA, SpA, OA 
and juvenile idiopathic arthritis (JIA). 
Figures 1-4 show illustrative US im-
ages of these diseases.
Methods
We carried out a literature search in 
PUBMED and EMBASE databases 
for English language articles published 
from January 2015 to December 2015.
We review all the published articles 
and selected the most relevant accord-
ing to the following criteria;  involv-
ing humans, focus on MSUS advance-
ments,  relevance to clinical rheumatol-
ogy, journal impact factor and expert 
opinion of the authors. We included 
original articles and international con-
sensus and recommendations. Reviews 
or abstracts from scientific congresses 
were not included.  
Rheumatoid arthritis
MSUS has shown validity and added 
value over clinical and radiographic 
assessment in improving diagnosis 
and monitoring of RA (4, 5). GS US is 
more sensitive than clinical evaluation 
in detecting intra-articular (i.e. synovi-
al hypertrophy and effusion) and peri-
articular inflammation (i.e. tenosyno-
vitis) as well as more sensitive than 
conventional radiography in detecting 
structural damage (i.e. bone erosions, 
tendon damage). Doppler mode, either 
colour Doppler (CD) or power Doppler 
(PD), is able to detect pathological syn-
ovial and tenosynovial flow, which is 
a validated marker of synovial inflam-
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matory activity (i.e. Doppler synovitis, 
Doppler tenosynovitis) that strongly 
predicts joint structural damage pro-
gression (4, 5).  
Validation
Kelly et al. (6) investigated the relation-
ship of GS and Doppler synovitis with 
histological synovial vascularity, angio-
genic/lymphangiogenic factors and cel-
lular mediators of inflammation in 12 
patients with treatment-naive early RA 
who underwent US-guided synovial bi-
opsy at the suprapatellar recess of the 
knee. GS and Doppler synovitis were 
measured quantitatively (i.e. pixel count 
for synovial area and synovial PD sig-
nal) and semiquantitatively (0–3 scale 
for GS synovial thickness and synovial 
PD signal). Quantitative and semiquan-
titative US parameters correlated with 
synovial vascular density and blood 
vessel number density. Quantitative PD 
correlated well with tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β and 
IL-6 gene expression (Spearman’s rho 
0.61, 0.69 and 0.59, respectively) and 
angiogenic factors such as vascular en-
dothelial growth factor (VEGF)-A and 
VEGF-R3. GS synovial area correlated 
significantly with proinflammatory cy-
tokine expression and angiogenic fac-
tors such as VEGF-A, Angiopoietin 2 
Fig. 1. Longitudinal ultrasound image of the dorsal aspect of a metacarpophalangeal joint that shows grey-scale synovial hypertrophy with high power 
Doppler signal in a patient with rheumatoid arthritis. mc: metacarpal bone; pp: proximal phalanx.
Fig. 2. Longitudinal ultrasound image of the patellar tendon that shows grey-scale distal enthesopathy and deep infrapatellar bursitis with power Doppler 
signal in a patient with psoriatic arthritis. t: tibia.
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and tyrosine kinase (Tie) 2. Regarding 
lymphangiogenesis, a significant corre-
lation was found between synovial area 
and VEGF-R3, VEGF-C, and podo-
planin (Spearman’s rho 0.61, 0.62 and 
0.71, respectively). The authors con-
cluded that both GS and PD synovitis 
reflect synovial inflammation in early 
RA. 
Abe et al. (7) studied the relation be-
tween PD-scored (0-3) synovial flow 
and synovial histological findings in 
215 joints (64 large joints and 151 
small joints) form 177 RA patients who 
underwent joint surgery. In both large 
and small joints, there was a strong 
correlation between the PD signal 
grade and Rooney total score (Spear-
man’s rho 0.76, p<0.001) and between 
the PD signal grade and five of the in-
dividual Rooney scores; synoviocyte 
hyperplasia (Spearman’s rho 0.55, 
p<0.001), fibrosis (Spearman’s rho 
-0.54, p<0.001), perivascular infiltrates 
of lymphocytes (Spearman’s rho 0.77, 
p<0.001), focal aggregates of lympho-
cytes (Spearman’s rho 0.68, p<0.001) 
and diffuse infiltrates of lymphocytes 
(Spearman’s rho 0.77, p<0.001). The 
authors also concluded that PD-de-
tected synovitis was a valid marker of 
synovial inflammation.
MSUS can be successfully used to 
guide synovial biopsy of large, medium 
size and small joints (8). Humby et al. 
(9) investigated the utility of minimally 
invasive, US-guided biopsies of small 
joints performed at baseline and after 
3 or 6 months of disease modifying an-
tirheumatic drug (DMARD) therapy in 
35 RA patients from two clinical trials. 
GS synovial thickness and synovial PD 
signal were semiquantitatively scored 
(0-3) before biopsy. Good quality syn-
ovial tissue that accurately reflected 
the synovial immune phenotype of 
the total joint was obtained in 80% of 
US-guided procedures when synovial 
thickness was graded ≥2 before biopsy 
In 100% of the procedures, sufficient 
RNA was extracted to permit molecu-
lar analysis. There was a significant 
correlation between change in sublin-
ing macrophage (CD68+) number and 
clinical response to treatment. Thus, 
the authors confirmed the validity of a 
technically simple procedure to obtain 
good quality synovial tissue from biop-
sies of small joints in RA.
The previous research group conducted 
another study (10) that aimed to as-
sess the tolerability, safety and yield of 
synovial tissue in early arthritis patients 
using the previously tested US-guided 
Fig. 3. Longitudinal ultrasound image of the medial tibiofemoral space that shows a tear of the anterior horn of the medial meniscus with a meniscal cyst 
extending to the pes anserinus area in a patient with early knee osteoarthritis. f: femur; t: tibia.
Fig. 4. Longitudinal ultrasound image of the anterior recess of the elbow that shows synovitis in a 
5-year-old patient with idiopathic juvenile arthritis. h: humerus; r: radius.
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synovial biopsy procedure in small, 
medium size and large joints. They 
carried out 93 biopsies (baseline and 
36 repeat biopsies at 6 months) of the 
knee, elbow, wrist, metacarpophalan-
geal (MCP) or proximal interphalangeal 
(PIP) joints from 57 patients. GS syno-
vial thickness and synovial PD signal 
were semiquantitatively scored (0–3) 
before biopsy. No significant complica-
tions were reported after the procedure. 
The majority (93%) of biopsies yield-
ing good quality tissue. RNA yield was 
good in all joints. Again, a prebiopsy 
high GS synovitis score was predictor 
of good quality and quantity of tissue 
and greater yield of RNA.
MSUS allows visualisation of a variable 
part of the articular cartilage. Onodera 
et al. (11) evaluated the validity of in 
vivo US scoring of metatarsal head ar-
ticular cartilage as compared to in vitro 
US scoring and histologic scoring in 15 
RA patients who underwent resection 
arthroplasty of the metatarsal heads. 
The articular cartilage was scored with 
US on a 1–6 scale of damage (1, blurred 
margin or partial lack of clarity, without 
thickness change; 6, no visualised carti-
lage band). The histologic scoring was 
performed blinded to the US findings 
and consisted of a 1–4 scale for the fol-
lowing changes; loss of matrix staining, 
surface fibrillation, deeper fissures or 
clefts, reduced thickness, and loss and 
erosion of cartilage. In vivo US scoring 
showed a significant correlation with 
both in vitro US scoring (Spearman’s 
rho 0.74, p<0.001) and histologic scor-
ing (Spearman’s rho 0.67, p<0.001).
Mandl et al. (12) conducted a study 
aimed at validating US for measuring 
metacarpal cartilage thickness using 
anatomical measurement of 5 cadaver 
specimens as gold standard as well as 
assessing the relation between US-
measured metacarpal cartilage thick-
ness and radiographic joint space in 35 
patients with RA. The results demon-
strated a substantial agreement between 
US and anatomical metacarpal cartilage 
thickness (intraclass correlation coef-
ficient 0.61). In addition, US metacar-
pal cartilage thickness of individual 
MCP joints showed a high correlation 
with individual MCP joint space width 
(Pearson’s r 0.72, p<0.001).
US operator-dependence is a major bar-
rier to full implementation in clinical 
practice. Brulhart et al. (13) evaluated 
the reproducibility of a semiquantita-
tive scoring system [Swiss Sonography 
in Arthritis and Rheumatism (SONAR) 
group] for synovitis and erosions in 
RA between 19 participants with vari-
ous levels of expertise in US, using 6 
US machines ranging from low to high 
quality. Concordance between ultra-
sonographers with high experience in 
US who used good quality machine 
was substantial (median kappa (κ) 0.64 
for GS and Doppler synovitis and 0.41 
for erosions). However, agreement was 
worse for less experienced participants 
and/or low quality machines. These 
results highlight the importance of ex-
perience in MSUS and machine quality 
for appropriate use of this imaging mo-
dality in clinical practice. 
Diagnostic performance
MSUS has been recommended to en-
hance the diagnostic capability of con-
ventional clinical and laboratory ap-
proach in patients with preclinical RA 
or early undifferentiated arthritis (14). 
Rakieh et al. (15) prospectively assessed 
the predictive value of clinical, imag-
ing, and serological features in relation 
to progression to inflammatory arthritis 
in 100 patients with non-specific MS 
symptoms and positive anticyclic citrul-
linated peptide (anti-CCP) antibodies. 
Fifty patients developed inflammatory 
arthritis after a median 7.9 months (0.1–
52.4), the majority (86%) fulfilling the 
2010 American College of Rheumatol-
ogy/European League Against Rheuma-
tism (EULAR) criteria for RA. Tender-
ness of hand or foot joints, early morn-
ing stiffness ≥30 min, high-positive au-
toantibodies, and positive PD synovial 
signal were predictors for high risk of 
progression to established arthritis. 
Assessment of inflammation 
MSUS has widely demonstrated great-
er sensitivity than clinical evaluation in 
detecting joint and tendon inflamma-
tion. This fact is particularly relevant 
in deep anatomic areas, which are dif-
ficult to assess by physical examina-
tion. Two studies (16, 17) compared 
MSUS and clinical assessment in the 
detection of synovitis in the elbow and 
ankle joints. The results confirmed that 
MSUS was able to detect subclinical 
synovitis and enthesopathy in elbows 
(synovitis in 17.3% and enthesopathy 
in 14.1% of clinically normal elbows 
from 181 patients with inflammatory 
joint diseases) as well as subclinical 
synovitis in ankles (tibiotalar synovitis 
in 35% of asymptomatic ankles from 
80 RA patients). 
The presence of concomitant diseases 
such as fibromyalgia (FMG) frequently 
interferes with clinical assessment of 
RA and lead to an overestimation of the 
disease activity. In this scenario, MSUS 
can provide us with a more objective 
measure of inflammatory activity. Two 
studies (18, 19) investigated US inflam-
matory findings in RA patients with and 
without concomitant FMG. The results 
of both studies were consistent; while 
composite indexes of disease activ-
ity such as the Disease Activity Score 
(DAS) 28 were greater in RA patients 
with FMG, GS synovitis and, particular-
ly Doppler synovitis did not differ in RA 
patients with and without FMG. Thus, it 
seems that US-assessed synovitis is not 
affected by FMG in RA patients. 
US-detected synovitis has been associ-
ated in varying degree with other clini-
cal and laboratory markers of inflam-
matory status or response to therapy 
in RA. In line with this, Hurnakova et 
al. (20) and Montoro et al. (21) evalu-
ated the association of US-determined 
(i.e. semiquantitative scores of GS and 
Doppler synovitis) RA activity and 
serum calprotectin and native comple-
ment components, respectively. Hur-
nakova et al. (20) found a significant 
correlation between calprotectin levels 
and Doppler synovitis (Spearman’s rho 
0.50, p<0.005). Montoro et al. (21) re-
ported that Doppler-determined disease 
inactive status but not clinically deter-
mined was associated with decrease in 
complement (C3) in RA patients treated 
with biologic therapy.
An important issue in clinical practice 
is whether MSUS can distinguish be-
tween joint inflammation due to RA or 
other diseases such as OA, which co-
exists with the former in many older 
patients. Glimm et al. (22) compared 
the amount (i.e. semiquantitative 0–3 
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score) and distribution of inflammation 
detected by GS and PD and fluores-
cence optical imaging in wrist and fin-
ger joints of 67 RA patients and 23 OA 
patients. GS US showed wrist and MCP 
joints mostly affected in RA and PIP 
and distal interphalangeal (DIP) joints 
in OA. Overall, PD synovitis was more 
frequent in RA patients than in OA pa-
tients except for DIP joints. 
Several studies have shown the capabil-
ity of US to detect relevant subclinical 
synovitis 
in RA patients in clinical remission 
treated with either synthetic or biologic 
DMARDs, which has been related to si-
lent structural damage progression and 
disease flare (23). Over the last year, 
a number of interesting papers on this 
topic have been published. Gärtner et 
al. (24), Harman et al. (25) and Tokai 
et al. (26) found subclinical GS and 
Doppler synovitis in a high percentage 
of RA patients in clinical remission. 
They also found that US-determined 
inactivity was related to longer dura-
tion of clinical inactivity. In addition, 
US inactivity was significantly associ-
ated with low radiographic structural 
damage (26).
Marks et al. (27) undertook a chal-
lenging study on tapering anti-TNF-α 
therapy, a recent strategy widely used in 
many countries, in 70 longstanding RA 
patients in sustained clinical remission 
with absence of PD synovitis in wrist 
and hand joints. Combined DAS28 and 
PDUS remission was maintained by 
96% of patients at 3 month follow-up, 
63% at 6 months, 37% at 9 months, 
and 34% at 18 months. The authors 
concluded that this combined clinical-
US strategy may be useful to optimise 
the selection of patients for anti-TNF-α 
dose reduction.  
Another relevant issue to address is 
the presence of US-detected synovitis 
in normal subjects. This is extremely 
important for an appropriate MSUS as-
sessment of RA inflammatory activity. 
Kitchen et al. (28) evaluated 40 joint 
of 30 healthy subjects. As expected, 
GS synovitis was more frequent than 
Doppler synovitis and increased with 
aging. PD synovial signal was found 
only in the wrist (8%) and first metatar-
sophalangeal (MTP) joint (3%).  
Quantification of inflammation
A great deal of interest has been focused 
on the feasibility of MSUS assess-
ment of RA inflammatory activity, i.e. 
whether a reduced number of joints can 
replace a comprehensive assessment of 
global synovitis in RA patients (29). 
Aga et al. (30) conducted a study on 
developing and validating optimal sets 
of joints and tendons for a feasible US 
assessment of joint inflammation in 227 
early RA and 212 established RA pa-
tients who started or change DMARD 
therapy. The authors identified 2 joint 
sets, i.e. bilateral 7 joints/2 tendons 
[MCP1, MCP2, PIP 3, radiocarpal, el-
bow, MTP1, MTP, tibialis posterior 
tendon, extensor carpi ulnaris tendon] 
and bilateral 9 joints/2 tendons [MCP5 
and MTP5 added to the above set] that 
performed well in terms of retaining the 
information from a comprehensive as-
sessment and responsiveness. However, 
Yoshimi et al. (31), obtained a 8-joint 
model [bilateral  MCP2, MCP3, wrist, 
and knee joints] that represented well a 
comprehensive US assessment of syno-
vitis in 234 RA patients.  
Doppler synovitis is usually assessed 
subjectively on a semiquantitative 0-3 
scale. In addition, Doppler assessment 
is particularly machine dependent. Two 
studied have addressed these relevant 
issues. Schmidt et al. (32) compared 
subjective scoring (0-3) with comput-
erised quantification of synovial Dop-
pler signal in 41 active RA patients. 
The distribution of the measured col-
our fraction by the assigned subjec-
tive scores was as follows; 0-6% for 
grade 1, >6–12% for grade 2 and >12% 
for grade 3. The authors suggested to 
reconsider the subjective scores for 
Doppler synovitis. On the other hand, 
Torp-Pedersen et al. (33) investigated 
the influence of PD and CD settings on 
different high- and intermediate-range 
US machines and evaluated the impact 
of these factors on Doppler scoring of 
synovitis. PD was more sensitive on 
half of the machines, whereas CD Dop-
pler was more sensitive on the other 
half. In addition, there was an average 
increase in both CD and PD of 78% us-
ing modified settings instead of factory 
setting. The authors highlighted the 
great influence of the US machine and 
the high impact of optimising Doppler 
settings on the quantification of inflam-
mation. 
Assessment of structural damage
MSUS is very sensitive in detecting 
early bone erosions in accessible joints 
such as those of hands and feet, which 
are target joints for early RA structural 
damage (34). However, the validity and 
reliability of US detection of bone ero-
sions have not been fully addressed. 
Three-dimensional (3D) volumetric 
probes potentially reduce the operator-
dependence and thus can be a useful 
tool in clinical practice and research. 
Peluso et al. (35) investigate the perfor-
mance of 3DUS in the detection of bone 
erosions in hand and wrist joints of 20 
early RA patients without erosions on 
radiography, using computed tomogra-
phy (CT) as the reference method. The 
sensitivity, specificity, positive predic-
tive value (PPV), and negative predic-
tive value (NPV) of 3DUS as compared 
with CT were 0.9, 0.55, 0.71, and 0.83, 
respectively. Most 3DUS false-nega-
tives were in the wrist joints and most 
3DUS false-positives were in the PIP 
joints.
Monitoring of therapeutic response
Responsiveness of MSUS has been 
worthy of attention by the scientific 
community (36). Two recent studies 
provided new insights into this field (36, 
37). D’Agostino et al. (37) undertook an 
international, multicentre, open-label, 
single-arm clinical trial to assess the re-
sponsiveness of a combined PD and GS 
synovitis score [Global OMERACT-
EULAR Synovitis Score (GLOESS)] 
in patients with RA starting abatacept. 
Early improvement was observed in the 
synovitis components either in MCP 
joints or in 22 bilateral joints (i.e. PD at 
week 1, synovial hypertrophy at week 
2, and joint effusion at week 4) with 
continuous improvement to week 24. 
DAS28 significantly decreased from 
weeks 1 to 24, reaching clinical mean-
ingful improvement at week 8.
Iagnocco et al. (38) assessed the short-
term (3 months) response to anti-
TNF-α therapy in 68 RA patients using 
a 6-joint (i.e. bilateral wrist, MCP2, 
and knee joints) GS (synovial hyper-
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trophy and effusion) and PD scoring 
(0–3) of synovitis. A significant de-
crease in the scores of the components 
of synovitis in all sites and in the global 
6-joint score was shown, which mod-
erately correlated with DAS28. These 
results confirmed the responsiveness of 
a feasible synovitis US assessment.
Prognostication of outcomes
There are previous solid results on the 
predictive value of US-detected synovi-
tis, mainly Doppler synovitis, either in 
clinically active or inactive RA patients 
in relation to structural damage progres-
sion and disease flare or relapse. The re-
sults of the study by Sreerangaiah et al. 
(39) confirmed again that Doppler-de-
tected synovial vascularity (either with 
2D or 3D US) in wrist and MCP joints 
was highly associated with structural 
damage progression at 12 months in 85 
RA patients with seropositive early RA. 
Naredo et al. (40) investigated the pre-
dictive value of US-detected synovitis 
in relation to failed tapering of bio-
logic therapy in 77 RA patients in sus-
tained clinical remission. At 12 months, 
45.5% of patients presented BT taper-
ing failure, 29.9% in the first 6 months. 
In logistic regression analysis, a base-
line DAS28 ≥2.2 and the presence of 
Doppler synovitis were identified as 
independent predictors of BT taper-
ing failure at 6 and 12 months, being 
the presence of Doppler synovitis the 
strongest predictor (odds ratio (OR) 
at 6 months 13.91 95%CI 3.44–56.29, 
p<0.0005; OR at 12 months 29.92, 95% 
CI 6.81–131.40, p<0.0005). These re-
sults suggested that US may contribute 
to the selection of appropriate patients 
for biologic therapy tapering. 
Spondyloarthritis
MSUS has been widely used to assess 
the peripheral joint, tendon and enthe-
sis involvement in SpA (41, 42).
Validation
Enthesitis is the hallmark of SpA. 
MSUS provides high-definition im-
ages of peripheral entheses. Falcao et 
al. (43) evaluated the construct validity 
of US-assessed Achilles enthesopahy 
in a 12-month longitudinal study on 
146 early SpA patients. Throughout the 
study, GS Achilles structure abnormali-
ties and entheseal Doppler signal were 
significantly associated with clinical 
[i.e. Ankylosing Spondylitis Disease 
Activity Score (ASDAS)] and labora-
tory markers of disease activity (i.e. C-
reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR)).  
Ventura-Ríos et al. (44) evaluated the 
inter-reader reliability between 18 ultra-
sonographers with different experience 
in 60 images of entheses from SpA pa-
tients and healthy controls. The results 
showed a variable agreement depend-
ing of the lesion assessed, being better 
between experts. Inter-reader reliability 
between experts was moderate for detec-
tion of structure and thickness changes, 
good for calcifications and bursitis, and 
excellent for erosions and entheseal 
Doppler signal. Again, the impact of ex-
perience in MSUS on a good reliability 
was evidenced in this study. 
Diagnostic performance
Milutinovic et al. (45) conducted a 
study aimed at testing the capability 
of MSUS to distinguish enthesopathy 
from patients with and without SpA. 
They blindly assessed enthesis thick-
ness, echogenicity, enthesophytes, PD 
signal and erosions in the entheses 
of plantar fascia, Achilles, patellar, 
quadriceps and common extensor ten-
dons in 76 patients with SpA, 26 with 
RA, and 25 with mechanically-related 
enthesopathy. Using logistic regression 
and receiver operating characteristic 
(ROC) curve analysis, they developed 
the Belgrade Ultrasound Enthesitis 
Score (BUSES), which represented a 
cumulative score of enthesis lesions. 
BUSES cut-off point ≥7 achieved ex-
cellent specificity (90.2%) for identify-
ing SpA patients. 
The capability of MSUS to detect a va-
riety of inflammatory findings in early 
psoriatic arthritis (PsA) was shown 
in the paper by Bandinelli et al. (46) 
who described wrist and hand US ab-
normalities in 112 cases. GS and PD 
synovitis, tenosynovitis, peritendinitis, 
and erosions were found independently 
of the clinical findings. In a study com-
paring US findings in the fingers of RA 
and PsA patients, Lin et al. (47) report-
ed the presence of soft tissue inflamma-
tion, enthesopathy and tenosynovitis 
only in PsA patients.  
Little attention has been paid to the US 
assessment of the joints of the anterior 
chest wall (ACW) in SpA. In a case-
control study, Verhoeven et al. (48) de-
scribed a frequent involvement of the 
ACW joints in SpA patients (36.5% 
of 131 patients), mainly US-detected 
bone changes in the sternoclavicular 
and manubriosternal joints that were 
associated with disease duration and 
radiographic sacroiliitis. 
Assessment of inflammation
Acquacalda et al. (49) compared US-
assessed enthesopathy in 10 entheses of 
34 patients with psoriasis (Ps) requir-
ing systemic treatment, 22 without MS 
symptoms and 12 with PsA. The au-
thors found a high prevalence of US ab-
normalities in Ps patients either with or 
without MS symptoms. After 6 months 
of systemic therapy, US morphological 
abnormalities significantly improved 
in Ps patients without MS and in PsA 
patients. 
The study by Janta et al. (50) dealt with 
US assessment of synovitis, tenosyno-
vitis, enthesopathy, and paratenonitis 
in PsA patients treated with full (74 
patients) and tapered (28 patients) dos-
age of biologic DMARDs. The authors 
found no significant differences be-
tween US variables, both for BM and 
CD between patients with full and ta-
pered dosage and between patients 
with and without concomitant synthetic 
DMARDs.
Monitoring of therapeutic response
Two recent studies by Ruta et al. (51) 
and Wang et al. (52) showed respon-
siveness of US-detected inflammatory 
changes at joint, tendon, and entheseal 
level in active SpA patients who began 
an effective treatment. Particularly, 
Wand et al. (52) demonstrated respon-
siveness of GS and PD abnormalities 
in the Achilles tendon of ankylosing 
spondylitis patients after 3 months of 
anti-TNF-α therapy. 
Prognostication of outcomes
Little research has been done on the 
predictive value of MSUS in PsA. El 
Miedany et al. (53) prospectively in-
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vestigated the predictive value of US-
detected inflammation in relation to ra-
diographic structural damage progres-
sion in 126 early PsA patients. Baseline 
GS score ≥2, PD score ≥2, presence of 
B-mode and Doppler enthesopathy as 
well as persistent US synovitis and en-
thesitis at 6 months were predictors of 
progressive early PsA and structural 
damage development.
International recommendations
Recently, EULAR has produced evi-
dence-based recommendations on the 
use of imaging in the clinical manage-
ment of both axial and peripheral SpA 
(54). According to these recommen-
dations, MSUS may be used to detect 
peripheral enthesitis, which may sup-
port the diagnosis of SpA or to detect 
peripheral synovitis, tenosynovitis and 
bursitis and to monitor synovitis and 
enthesitis in peripheral SpA.  
Osteoarthritis
MSUS offers a comprehensive assess-
ment of the OA joint (55, 56).
Validation
Again, US reliability has been notewor-
thy for international research groups. 
Bruyn et al. (57) on behalf of the 
OMERACT MSUS group assessed the 
intra- and interobserver reliability of 
MSUS for evaluating inflammatory and 
structural abnormalities in patients with 
knee OA. Eleven experienced ultra-
sonographers semiquantitatively scored 
knee synovitis, osteophytes, femoral 
cartilage damage and meniscal damage. 
Intra- and interobserver reliability were 
moderate to good for synovitis (mean κ 
0.67 and 0.52, respectively), and fair to 
good for cartilage damage, medial me-
niscal damage and osteophytes (mean κ 
0.55 and 0.34, 0.75 and 0.56, 0.73 and 
0.60, respectively).
Koski et al. (58) also investigated the 
intra- and inter-reader reliability of 
MSUS and radiography for detecting 
and semiquantitatively scoring osteo-
phytes in the tibiofemoral joint between 
14 readers, using a novel reference at-
las as support. Overall, intra- and inter-
reader US and radiography agreements 
were substantial (κ 0.60–0.72). US 
detected more osteophytes than CR at 
both the medial (65% vs. 48%) and lat-
eral (70% vs. 60%) compartments. 
Monitoring of therapeutic response
There is little information of the re-
sponsiveness of MSUS findings in OA. 
The study by Keen et al. (59) aimed 
to test whether US was able to detect 
synovial response to intra-articular 
corticosteroid (IACS) injections in 35 
patients with knee OA. GS synovial 
thickness and PD score decreased in 16 
and 13, respectively of 19 patients who 
received IACS injection and both were 
substantively associated with reduction 
in pain ≥ to the minimum clinically im-
portant improvement. 
Prognostication of outcomes
The role that inflammation plays in the 
pathogenesis of OA is under investi-
gation. Over the last year, four novel 
studies have dealt with this issue, two 
of them focused on hand OA (60, 61) 
and two studies on knee OA (62, 63). 
Kortekaas et al. (60) and Mancarella 
et al. (61) investigated the longitudinal 
association between US-detected in-
flammatory findings and radiographic 
progression in patients with hand OA 
(56 and 22 patients, respectively) after 
2-4 years of followup. Both groups ob-
tained comparable results; PD synovitis 
was associated with radiographic wors-
ening, particularly with bone erosion 
development or progression. However, 
in the study by Kortekaas et al. (60) GS 
synovial thickening was also associated 
with erosive deterioration.  Mathiessen 
et al. (62) assessed the predictive value 
of US-detected knee inflammation in 
relation to radiographic progression in 
78 patients with knee OA. In this study, 
US-detected synovitis predicted OA 
progression according to the Kellgren-
Lawrence (K-L) scale after 5 years of 
followup as follows; for GS synovi-
tis grade 1, OR 2.8 (95% CI 1.8–4.2); 
grade 2, OR 3.6 (95% CI 2.2–5.8); and 
grade 3, OR 15.2 (95% CI 6.9-33.6) and 
for PD synovitis grade 1, OR 2.9 (95% 
CI 1.2–6.8);  and grades 2–3, OR 12.0 
(95% CI 3.5–41.0). In 125 patients with 
knee OA, Bevers et al. (63) found that 
the presence on US mainly of Baker’s 
cyst but also synovial hypertrophy were 
associated with radiographic progres-
sion after 2 years of followup. Further 
studies on potential therapeutic strate-
gies targeting inflammation in OA are 
warranted. 
Assessment of associated 
abnormalities
Periarticular complaints are frequent 
in knee OA. Two recent studies (64, 
65) evaluated the pes anserinus ten-
don insertion in patients with knee OA. 
Toktas et al. (64) found that the mean 
pes anserinus thickness was signifi-
cantly greater in 157 patients with knee 
OA with or without clinical anserine 
tendinitis-bursitis syndrome than in 30 
healthy controls. In addition, the mean 
pes anserinus thickness in OA knees 
K-L graded 3 and 4 was greater than 
in OA knees K-L graded 1 and 2, in-
dependently of the presence of anserine 
symptoms. Uysal et al. (65) found pes 
anserine bursitis in 20% of 85 patients 
with knee OA. There was a significant 
positive correlation between both the 
longest length and area of the bursitis 
and the OA K-L grade. Both groups 
concluded that MSUS may be helpful 
to detect pes anserinus abnormalities 
associated with knee OA that can ben-
efit from specific treatment. 
Juvenile idiopathic arthitis
Over the past years, MSUS has been 
increasingly implemented in paediatric 
rheumatology. The non-invasive and 
friendly nature of this imaging modal-
ity makes it particularly suitable for 
children care (66, 67). 
Validation
The OMERACT MSUS group has put 
much effort into validating MSUS in 
paediatric rheumatic diseases, starting 
with JIA. Two novel studies (68, 69) 
have provided extremely useful data 
on the normal age-related sonoanatomy 
and vascularisation of joints and en-
theses in healthy children. In addition, 
the OMERACT MSUS group has pro-
duced agreed definitions for the com-
ponent of the normal paediatric joints 
(i.e. articular bone, cartilage, joint 
capsule, epiphyseal ossification centre, 
and synovial membrane) whose appli-
cability has been successfully tested in 
standardised US scans of representative 
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normal joints by an international pan-
nel (70).  
Pradsgaard et al. (71) carried out a study 
aiming at comparing US with magnetic 
resonance imaging (MRI) measure-
ments of distal femoral cartilage thick-
ness in the knee joint of 23 children with 
oligoarticular JIA. The authors found a 
high level of agreement between MRI 
and US measurements of the cartilage 
thickness (Spearman’s Rho 0.70–0.86).
Assessment of inflammation
Synovial angiogenesis is involved in 
the pathogenesis of JIA. Świdrowska 
et al. (72) assessed the relation between 
the levels of angiogenic markers and 
US inflammatory findings in 43 early 
JIA children and 23 healthy controls. 
PD-detected joint vascularisation cor-
related with serum VEGF, supporting 
the inflammatory nature of both bio-
markers. 
Management
Nieto et al. (73) evaluated the extent 
to which MSUS may influence the di-
agnosis and management decisions 
in daily clinical practice in paediatric 
rheumatology. Of 111 patients who at-
tended a busy paediatric rheumatology 
unit over a 3-month period (45.9% di-
agnosed with JIA), 65 (58.6%) patients 
qualified for MSUS. Of the 65 patients 
undergoing MSUS, in 38 (58.5%) pa-
tients there was a change in diagnosis, 
therapeutic decisions or both following 
the MSUS information. The authors 
concluded that MSUS may play a rel-
evant role in local diagnosis and thera-
peutic decisions and could help in the 
management of rheumatic diseases in 
children.
The utility of US as guidance for in-
jection targeting challenging anatomic 
area is supported by the study by Young 
et al. (74) which described a successful 
and safe technique for US-guided corti-
costeroid injection in the subtalar joint 
of 122 children with JIA. 
International recommendations
Recently, EULAR and the Paediat-
ric Rheumatology European Society 
(PRES) have developed evidence-based 
points to consider for the use of imaging 
in the diagnosis and management of JIA 
in clinical practice (75). This document 
highlights the superiority of MSUS over 
clinical assessment in detection of joint 
inflammation and thus MSUS should be 
considered in diagnosis JIA and assess-
ment of extension of joint involvement. 
In addition, MSUS may be used to de-
tect early joint damage and to monitor 
disease activity as well as US-detected 
inflammation may be considered a prog-
nostic indicator. Finally, US can be used 
for accurate placement of intra-articular 
injections. 
In conclusion, 2015 has provided us 
with novel insights into the validity 
and utility of MSUS in arthritis that en-
hance the applicability of this imaging 
modality in rheumatologic practice and 
encourage further research in this field.
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